Joseph Stringer
Stock Analyst at Needham
(4.58)
# 214
Out of 5,072 analysts
323
Total ratings
49.65%
Success rate
37.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Downgrades: Hold | n/a | $219.75 | - | 17 | Nov 14, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $133 → $140 | $127.51 | +9.80% | 9 | Nov 13, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $122 → $120 | $107.42 | +11.71% | 27 | Nov 7, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $78 → $90 | $82.70 | +8.83% | 25 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $65 | $71.56 | -9.17% | 19 | Oct 27, 2025 | |
| MRNA Moderna | Reiterates: Hold | n/a | $25.01 | - | 9 | Oct 20, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 → $35 | $31.21 | +12.14% | 24 | Oct 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $377 → $478 | $445.12 | +7.39% | 23 | Jul 31, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $15.17 | +84.57% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $6.39 | +119.09% | 18 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $4.32 | +154.63% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $29 | $21.59 | +34.32% | 20 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $432.17 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $49.65 | +81.27% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.43 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.58 | +532.91% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $24.81 | +49.13% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $19.96 | -9.82% | 2 | Aug 24, 2021 |
Cidara Therapeutics
Nov 14, 2025
Downgrades: Hold
Price Target: n/a
Current: $219.75
Upside: -
Gilead Sciences
Nov 13, 2025
Maintains: Buy
Price Target: $133 → $140
Current: $127.51
Upside: +9.80%
Rhythm Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $122 → $120
Current: $107.42
Upside: +11.71%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $78 → $90
Current: $82.70
Upside: +8.83%
Avidity Biosciences
Oct 27, 2025
Downgrades: Hold
Price Target: $65
Current: $71.56
Upside: -9.17%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $25.01
Upside: -
Stoke Therapeutics
Oct 10, 2025
Maintains: Buy
Price Target: $22 → $35
Current: $31.21
Upside: +12.14%
Alnylam Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $377 → $478
Current: $445.12
Upside: +7.39%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $15.17
Upside: +84.57%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $6.39
Upside: +119.09%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $4.32
Upside: +154.63%
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $21.59
Upside: +34.32%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $432.17
Upside: -
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $49.65
Upside: +81.27%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.43
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.58
Upside: +532.91%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $24.81
Upside: +49.13%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $19.96
Upside: -9.82%